Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leukemia - 1 Sept 2025

Yang Chang, Kang Yuan-Yuan, Zhu Chen-Ying, Ma Yafang, Yu Pei-Han, Yang Tao, Liu Yong-Qin, Zhang Ze-Yan, Suzuki Noriyuki, Ogra Yasumitsu, Björklund Mikael, Naranmandura Hua

Abstract excerpt

BCR::ABL1 oncofusion protein drives Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), making it a critical therapeutic target. Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have revolutionized the treatment of Ph+ ALL patients. However, mutations in the kinase domain of BCR::ABL1 commonly impair the sensitivity to TKIs, resulting in drug resistance and poor prognosis in Ph+ ALL....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heat-Shock Response

Share to Philadelphia Chromosome

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Proteolysis

Share to Proto-Oncogene Proteins c-abl

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 40696139
DOI: 10.1038/s41375-025-02709-0

Genes

BCR
ABL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia.PMID 40696139Read ↗

Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors.Semantic proximity Read ↗

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human LeukemiaSemantic proximity Read ↗

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Semantic proximity Read ↗

Targeting BCR-ABL1-positive leukaemias: a review articleSemantic proximity Read ↗

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemiaSemantic proximity Read ↗

Structure and dynamic regulation of Abl kinases.Semantic proximity Read ↗

Heat shock proteins in cancer: chaperones of tumorigenesis.Semantic proximity Read ↗

Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemiaSemantic proximity Read ↗

Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive LeukemiaSemantic proximity Read ↗

Proximity-induced rewiring of oncogenic kinase triggers apoptosisSemantic proximity Read ↗

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.Semantic proximity Read ↗

Novel Insights into YB-1 Signaling and Cell Death DecisionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.